Back to top
more

Centene (CNC)

(Real Time Quote from BATS)

$25.87 USD

25.87
11,970,439

-0.34 (-1.30%)

Updated Aug 5, 2025 02:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 1% (244 out of 246)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.

Zacks Equity Research

Luminex (LMNX) Banks on Solid Product Line, Competition Rife

by Zacks Equity Research

Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.

    Zacks Equity Research

    Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis

    by Zacks Equity Research

    Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.

      Zacks Equity Research

      Hologic Banks on Diagnostics, GYN Surgical Prospects Bright

      by Zacks Equity Research

      Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.

        Zacks Equity Research

        Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too

        by Zacks Equity Research

        CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.

          Zacks Equity Research

          Inogen (INGN) Gains on Diverse Product Line, Competition Rife

          by Zacks Equity Research

          Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.

            Zacks Equity Research

            Exactech (EXAC) Gets Acquired by TPG Capital, Goes Private

            by Zacks Equity Research

            TPG Capital acquires Exactech (EXAC) with a view to cash in on its resources and gain a foothold in the orthopedics market.

              Zacks Equity Research

              DaVita (DVA) to Report Q4 Earnings: What's in the Cards?

              by Zacks Equity Research

              DaVita's (DVA) fourth-quarter results to hurt from lackluster revenues stemming from high debts and labor union hurdles.

                Zacks Equity Research

                Can Geographical Sales Aid DENTSPLY's (XRAY) Q4 Earnings?

                by Zacks Equity Research

                DENTSPLY (XRAY) anticipates lower regional sales to dent results in Q4. The company continues to focus on operational excellence.

                  Zacks Equity Research

                  Centene (CNC) Tops Q4 Earnings and Revenues

                  by Zacks Equity Research

                  Centene's (CNC) fourth - quarter operating earnings and revenues handily surpassed our Zacks Consensus Estimate.

                    Zacks Equity Research

                    Medical Stocks Reporting Q4 Earnings on Feb 6: CNC, WCG, HQY

                    by Zacks Equity Research

                    Medical stocks' fourth-quarter results are likely to benefit from higher membership, increase in premium, partly offset by high costs.

                      Zacks Equity Research

                      Can Solid Medicaid Business Boost Centene (CNC) Q4 Earnings?

                      by Zacks Equity Research

                      Centene's (CNC) fourth-quarter results are expected to be supported by membership growth and cost-saving initiatives.

                        Zacks Equity Research

                        Why Centene Corporation (CNC) Might Surprise This Earnings Season

                        by Zacks Equity Research

                        Centene (CNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                          Zacks Equity Research

                          4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now

                          by Zacks Equity Research

                          Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.

                            Zacks Equity Research

                            Will Higher Membership, Revenues Aid Cigna (CI) Q4 Earnings?

                            by Zacks Equity Research

                            Cigna's (CI) Q4 earnings should likely be aided by higher revenues from its healthcare, global supplement units, partly offset by Medicare membership loss.

                              Zacks Equity Research

                              AET vs. HCA: Which Stock is Poised for Better Q4 Earnings?

                              by Zacks Equity Research

                              Let us try to find out which stock between Aetna (AET) and HCA Healthcare (HCA) is better positioned for an earnings beat in the fourth quarter

                                Zacks Equity Research

                                AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer

                                by Zacks Equity Research

                                AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.

                                  Zacks Equity Research

                                  Will HCA Healthcare's (HCA) Earnings Beat Estimates in Q4?

                                  by Zacks Equity Research

                                  HCA Healthcare's (HCA) fourth-quarter results are expected to be driven by higher admissions

                                    Zacks Equity Research

                                    Varian Medical (VAR) Beats Q1 Earnings & Revenue Estimates

                                    by Zacks Equity Research

                                    HyperArc and Halcyon platforms drive Varian Medical's (VAR) Q1 results.

                                      Zacks Equity Research

                                      Health Insurers Bask Under Rising Insured, Medicare Business

                                      by Zacks Equity Research

                                      Health insurers have capitalized on a surge in insured rates by raking in members, who added to their top-line growth.

                                        Zacks Equity Research

                                        PerkinElmer Hits 52-Week High: What's Driving the Stock?

                                        by Zacks Equity Research

                                        PerkinElmer's (PKI) shares hit a new 52-week high on the back of broad product spectrum and acquisition-led growth.

                                          Swarup Gupta headshot

                                          4 Great Healthcare Stocks to Buy Ahead of Q4 Earnings

                                          by Swarup Gupta

                                          An ageing population and steady demand for healthcare services continue to make stocks from the sector a lucrative option.

                                            Zacks Equity Research

                                            CVS Health Grows on Pharmacy Services, Retail Remains a Drag

                                            by Zacks Equity Research

                                            CVS Health's (CVS) strong Pharmacy Services business continues to gain from a sturdy Specialty Pharmacy. However, its highly competitive retail pharmacy business raises concern.

                                              Zacks Equity Research

                                              Can Tenet Healthcare (THC) Get Back on Growth Path in 2018?

                                              by Zacks Equity Research

                                              Shares of Tenet Healthcare (THC) have lost significantly last year owing to lower revenues, weak margins, high bad debts and expenses.

                                                Zacks Equity Research

                                                Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?

                                                by Zacks Equity Research

                                                Intuitive Surgical (ISRG) is expected to witness growth across da Vinci Surgical and Service segments. Instruments and accessories revenues are also expected to increase year over year.

                                                  Zacks Equity Research

                                                  DaVita (DVA) Partners with Epic to Launch EHR for Patients

                                                  by Zacks Equity Research

                                                  DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.